GlassScriptPhysician profile
Debra Lesin
NPI 1952701500
$1,723.84
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $835 · 2022: $889.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $280.92 | 2021-2022 | |
| Dexcom, INC. | $274.42 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $264.68 | 2021-2022 | |
| Novo Nordisk INC | $215.93 | 2021-2022 | |
| Insulet Corporation | $210.01 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.74 | 2021-2022 | |
| Lilly USA, LLC | $95.39 | 2021-2022 | |
| Zealand Pharma US, INC. | $76.94 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $46.70 | 2021-2022 | |
| Medtronic, INC. | $43.78 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.23 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.10 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Lesin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.